Lipid-lowering drugs and risk for cancer

Current Atherosclerosis Reports

Volumn 11, Issue 5, 2009, Pages 350-357

  Pedersen, Terje R ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; AORTA STENOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENICITY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; GENOTOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID DEGRADATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

EID: 68449098086     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0053-3     Document Type: Review

References (55)

1. Jacobs D, Blackburn H, Higgins M, et al.: Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation 1992, 86:1046-1060.
2. Chen Z, Peto R, Collins R, et al.: Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991, 303:276-282.
3. Committee of Principal Investigators: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978, 40:1069-1118.
4. Committee of Principal Investigators: WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Lancet 1984, 324:600-604.
5. Davey Smith G, Pekkanen J: Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992, 304:431-434.
6. Hulley SB, Walsh JM, Newman TB: Health policy on blood cholesterol. Time to change directions. Circulation 1992, 86:1026-1029.
7. Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: A quantitative review od primary prevention trials. BMJ 1990, 301:309-314.
8. Oliver MF: Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991, 337:1529-1531.
9. Drazen JM, D'Agostino RB, Ware JH, et al.: Ezetimibe and cancer-an uncertain association. N Engl J Med 2008, 359:1398-1399.
10. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. BMJ 1994, 308:373-379.
11. Scandinavian Simvastatin Survival Study (4S) Group: Randomized trial of cholesterol-lowering in 4444 patients with coronary heart-disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
12. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
13. ALLHAT Officers and Coordinators: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3042.
14. The LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
15. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002, 360:1623-1630.
16. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55-60.
17. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
18. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007, 50:409-418.
19. Cannon CP, Braunwald E, Mccabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
20. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes-phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
21. Larosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
22. Pedersen TR, Faergeman O, Kastelein JJ, et al.: High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. JAMA 2005, 294:2437-2445.
23. Holdaas H, Fellström B, Jardine AG, et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
24. Browning DR, Martin RMA Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2006, 120:833-843.
25. Karp I, Behlouli H, LeLorier J, Pilote L: Statins and cancer risk. Am J Med 2008, 121:302-309.
26. Kuoppala J, LaAminpää A, Pukkala E: Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
27. Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
28. Einhorn N, Eklund G, Franzén S, et al.: Late side effects of chemotherapy in ovarian carcinoma. A cytogenic, hematologic, and statistical study. Cancer 1982, 49:2234-2241.
29. Greene MH, Moloney WC, Boice JD: Melphalan may be more potent leukemogen than cyclophosphamide. Ann Intern Med 1986, 105:360-367.
30. Shell AG, Disney AP, Mathew TH, et al.: Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transpl Proc 1997, 29:825-827.
31. Lipid Research Clinics Investigators: The Lipid Research Clinics coronary primary prevention trial: Results of 6 years of post-trial follow-up. Arch Intern Med 1992, 152:1399-1410.
32. The LIPID Study Group: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002, 359:1379-1387.
33. Ford I, Murray H, Packard CJ, et al.: Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007, 357:1477-1486.
34. Strandberg TE, Pyörälä K: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
35. Rosseb: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
36. Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357-1366.
37. Alsheikh-Ali AA, Karas RH: Ezetimibe, and the combination of ezetimibe/ simvastatin, and risk of cancer: A post-marketing analysis. J Clin Lipidol 2009 (in press).
38. Halleck M, Davis HR, Kirschmeier P, et al.: An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 2009 (in press).
39. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
40. Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641-651.
41. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
42. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
43. FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366:1849-1861.
44. Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. I Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
45. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
46. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/Tex-CAPS. JAMA 1998, 279:1615-1622.
47. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
48. Sever PS, Dahlöf B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
49. Colhoun HM, Beteridge DJ, Durrinigton PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicenter randomised placebo-controlled trial. Lancet 2004, 364:685-696.
50. Wanner C, Krane V, März W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
51. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCLE) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
52. Kjekshus J, Apetrei E, Barrios V, et al.: For the CORONA group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
53. GISSI HF Investigators: Effect of rosuvastatin in patients with chronic heart fialure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
54. Ridker PM, Danielson E, Fonseca FAH, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
55. Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.